Real-World Outcomes for Standard-ofCare Treatments in Patients with Relapsed/Refractory Multiple Myeloma

被引：3

作者：

Delforge, Michael ^{[1
]}

Vekemans, Marie-Christiane ^{[2
]}

Anguille, Sebastien ^{[3
,4
]}

Depaus, Julien ^{[5
]}

Meuleman, Nathalie ^{[6
]}

Van de Velde, Ann ^{[7
]}

Van de Broek, Isabelle ^{[8
]}

Strens, Danielle ^{[9
]}

Van Hoorenbeeck, Sandra ^{[10
]}

Moorkens, Evelien J. ^{[10
]}

Diels, Jorks ^{[11
]}

Ghilotti, Francesca ^{[12
]}

Dalhuisen, Sander ^{[13
]}

Vandervennet, Sophie ^{[10
]}

机构：

[1] Univ Ziekenhuizen Leuven, Leuven, Belgium

[2] Clin Univ St Luc, Brussels, Belgium

[3] Univ Antwerp, Vaccine & Infect Dis Inst, Lab Expt Hematol, Fac Med & Hlth Sci, Antwerp, Belgium

[4] Univ Antwerp Hosp, Div Hematol & Ctr Cell Therapy Regenerat Med, Edegem, Belgium

[5] Catholic Univ Louvain, Dept Haematol, CHU UCL Namur, Yvoir, Belgium

[6] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[7] Heilig Hartziekenhuis, Lier, Belgium

[8] AZ Nikolaas, Haematol, St Niklaas, Belgium

[9] Realidad bvba, Grimbergen, Belgium

[10] Janssen Cilag NV, Beerse, Belgium

[11] Janssen Pharmaceut NV, Beerse, Belgium

[12] Janssen Cilag SpA, Cologno Monzese, Italy

[13] Janssen Cilag BV, Breda, Netherlands

来源：

关键词：

D O I：

10.1182/blood-2021-146250

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4075

引用

页数：4